drugset / Trial / NCT00022282

AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00022282

Phase 2 Completed AEterna Zentaris
Open-labelTreatment

Summary

RATIONALE: AE-941 may help to slow the growth of multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of neovastat in treating patients who have relapsed or refractory multiple myeloma.

Timeline

Start
2001-04
Primary completion
2007-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AE-941 Unknown Oral

Indications